Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores

Autor: Josefine Gerhardt, Ferdinand Hofstädter, Florian R. Fritzsche, Helge Seifert, Tullio Sulser, Michael Müntener, Ashkan Mortezavi, Glen Kristiansen, Kristian Ikenberg, Maximilian Burger, Ursina Zuerrer-Haerdi, Irina Hofmann, Thomas Hermanns, Maurizio Provenzano, Silvia Behnke, Peter J. Wild, Holger Moch
Přispěvatelé: University of Zurich, Kristiansen, G
Rok vydání: 2010
Předmět:
Male
Oncology
PCA3
medicine.medical_specialty
Cancer Research
Neoplasms
Hormone-Dependent
medicine.medical_treatment
Prostatic Hyperplasia
610 Medizin
RNA-binding protein
610 Medicine & health
lcsh:RC254-282
Immunoenzyme Techniques
Prostate cancer
1311 Genetics
Prostate
Surgical oncology
Internal medicine
10049 Institute of Pathology and Molecular Pathology
medicine
Genetics
Humans
1306 Cancer Research
Aged
Neoplasm Staging
Aged
80 and over
ddc:610
business.industry
Insulin
Growth factor
Prostatic Neoplasms
RNA-Binding Proteins
Middle Aged
Prognosis
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Rate
10062 Urological Clinic
medicine.anatomical_structure
Tissue Array Analysis
Case-Control Studies
Cancer research
2730 Oncology
business
Research Article
Hormone
Zdroj: BMC Cancer, Vol 10, Iss 1, p 341 (2010)
BMC Cancer
DOI: 10.5167/uzh-35329
Popis: Background The oncofetal protein insulin-like growth factor II mRNA binding protein 3 (IMP3) is an important factor for cell-migration and adhesion in malignancies. Recent studies have shown a remarkable overexpression of IMP3 in different human malignant neoplasms and also revealed it as an important prognostic marker in some tumor entities. To our knowledge, IMP3 expression has not been investigated in prostate carcinomas so far. Methods Immunohistochemical stainings for IMP3 were performed on tissue microarray (TMA) organized samples from 507 patients: 31 normal prostate tissues, 425 primary carcinomas and 51 prostate cancer metastases or castration-resistant prostate cancers (CRPC). IMP3 immunoreactivity was semiquantitatively scored and correlated with clinical-pathologic parameters including survival. Results IMP3 is significantly stronger expressed in prostate carcinomas compared to normal prostate tissues (p < 0.0001), but did not show significant correlation with the pT-stage, the proliferation index (MIB1), preoperative serum PSA level and the margin status. Only a weak and slightly significant correlation was found with the Gleason score and IMP3 expression failed to show prognostic significance in clinico-pathological correlation-analyses. Conclusions Although IMP3 is overexpressed in a significant proportion of prostate cancer cases, which might be of importance for novel therapeutic approaches, it does not appear to possess any immediate diagnostic or prognostic value, limiting its potential as a tissue biomarker for prostate cancer. These results might be corroborated by the fact, that two independent tumor cohorts were separately reviewed.
Databáze: OpenAIRE
Externí odkaz: